Drug absorption from gastrointestinal tract is mainly influenced by solubility and permeability. As a technique of the improvement of solubility, micronization, amorphousization and the addition of surfactant such as Tween 80 and Captisol ® are well known. As for the improvement of permeability, the use of absorption enhancers is well known, [1][2][3][4][5][6][7][8][9][10][11] but the practical use of them has been very limited 12,13) because of the potential local toxicity to gastrointestinal mucosa. 2,4) In order to develop the safe formulation that can improve the absorption of drugs categorized into BCS Class IV such as rebamipide, [14][15][16][17][18][19][20] we have compared the suppository that contains sodium laurate (C12) as an absorption enhancer and taurine (Tau) as a cytoprotective adjuvant with the commercial suppository that contains sodium caprate (C10) as an absorption enhancer. [21][22][23] We have found that C12, a mediumchain fatty acid salt, is a promising absorption enhancer and better than C10 in terms of the absorption improving ability, 24) and that Tau has the most effective cytoprotective activity among amino acids examined. 25) Cytoprotective action by Tau has been evidenced by both biochemical [25][26][27] and histopathological 25) approaches and it has been partially related with the suppression of intracellular Ca 2ϩ level elevated by C12 and the inhibition of histamine release induced by C12. L-Glutamine (L-Gln) also has the cytoprotective action, which is partially attributed to the induction of heat-shock protein 70 (HSP70), 27) a factor protecting cells from injuries caused by several kinds of stresses. 28,29) Furthermore, basic studies for suppository were performed in rats by administering the fatty or water-soluble base preparation containing rebamipide, C12 and Tau or L-Gln into rats. The combinatorial use of them, especially for the fatty base (FB) suppository, has been evidenced to be promising in terms of both improvement of bioavailability and safety to rat rectal mucosa.30) However, the success in the scaling-up study must be necessary for developing the formulation available for human use.In the present study, we have, therefore, performed the scaling-up study of animal and formulation size using FB suppositories of rebamipide and have compared our new preparations with the commercial suppository containing C10 (15 or 25 mg) in terms of the drug dissolution, absorption improvement and safety to the rectal mucosa of rabbits.
MATERIALS AND METHODSMaterials C12, C10 and Tau were purchased from Tokyo Chemical Industry Co. (Tokyo, Japan). Hydroxypropyl methylcellulose (HPMC) TC-5E (HPMC 2910) was purchased from Shin-etsu Kagaku Co. (Tokyo). Witepsol ® H-15 was obtained from Mitsuba Boueki Co. Ltd. (Tokyo). Rebamipide and OPC-12853, an internal standard, were obtained from Otsuka Pharmaceutical Co. Ltd. (Tokushima, Japan). All other reagents were analytical grade commercial products.Animals Male Japan-White rabbits (Kitayama Labes, Ina, Japan), maintained at 23°C and 60% hum...